摘要
不能手术切除的晚期胰腺癌预后极差并伴有全身衰竭症状 ,临床尚无有效的化疗药物和治疗方案。健择是 30年来美国FDA首次批准的用于治疗晚期胰腺癌的有效药物。临床研究表明 ,与现行的化疗药物氟尿嘧啶 ( 5 FU)比较 ,健择能有效的改善晚期胰腺癌病人的疾病相关症状 ,延长生存期。而临床受益反应作为评判指标的应用为 。
Purpose:Patients with unresectable advanced pancreatic carcinoma have a poor prognosis and suffer debilitating disease related symptoms. There have been no effective drugs and regimens in patient that affect outcome in clinic. Gemzar is the first drug approved by the FDA in more than 30 years for the treatment of patients with advanced pancreatic carcinoma. The clincial studies have shown that Gemzar treated patients had a significant improvement in disease related symptoms and prolonged overall survival compared with the control therapy (5 FU). Moreover, the clinical response benefits has become an evaluation endpoint that provides a new measurement standard for improvement of quality of life in patients with pancreas cancer.
出处
《中国癌症杂志》
CAS
CSCD
2000年第5期434-437,共4页
China Oncology
关键词
晚期
胰腺癌
健择
药物疗法
advanced pancreatic carcinoma
gemzar
clinical benefits response
